CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

• click to rate

  Posted by Two Blokes Jun 25 - Filed in Stock - 3 views
  
  CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.